Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome

Infection

Volumn 44, Issue 1, 2016, Pages 93-101

  Boesecke, Christoph ^a   Ingiliz, Patrick ^b   Reiberger, Thomas ^c   Stellbrink, Hans Jürgen ^d   Bhagani, Sanjay ^e   Page, Emma ^f   Mauss, Stefan ^g   Lutz, Thomas ^h   Voigt, Esther ⁱ   Guiguet, Marguerite ^j   Valantin, Marc Antoine ^k   Baumgarten, Axel ^b   Nelson, Mark ^f   Vogel, Martin ^a   Rockstroh, Jürgen K ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Royal National Institute of Blind People   (United Kingdom)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Infektionsmedizinisches Centrum Hamburg   (Germany)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^g Center for HIV and Hepatogastroenterology   (Germany)

^h Infektiologikum   (Germany)

ⁱ Praxis am Ebertplatz   (Germany)

^j INSERM   (France)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

Acute HCV treatment; Acute hepatitis C; HCV; HIV; MSM

Indexed keywords

PEGINTERFERON; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ADULT; ARTICLE; DISEASE TRANSMISSION; EUROPE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; MONOTHERAPY; TREATMENT DURATION; TREATMENT OUTCOME; CLASSIFICATION; COINFECTION; COMBINATION DRUG THERAPY; COMPLICATION; GENETICS; HEPACIVIRUS; HIV INFECTIONS; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84944704132     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-015-0856-9     Document Type: Article

References (41)

1. Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS. 2009;23:F1–7.
2. Fierer D, Fishman S, Uriel A, et al. Characterization of an outbreak of acute HCV infection in HIV-infected men in New York city. In: 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada; 2009; abstract 802.
3. Luetkemeyer A, Hare CB, Stansell J, et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;41:31–6.
4. Matthews G, Hellard M, Haber P, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian trial in acute hepatitis C. Clin Infect Dis. 2009;48:650–8.
5. Yaphe S, Bozinoff N, Kyle R, Shivkumar S, Pai NP, Klein M. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex Transm Infect. 2012;88:558–64.
6. Thomson EC, Nastouli E, Main J, et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS. 2009;23:89–93.
7. Jones L, Uriel A, Kaplan D, et al. Natural history and treatment outcome of acute hepatitis C with and without HIV co-infection in a North American cohort. In: AASLD 2008 Meeting; San Francisco, USA; 2008; abstract 1838.
8. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–6.
9. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–6.
10. Soriano V, Mocroft A, Rockstroh J, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis. 2008;198:1337–44.
11. Gilleece YC, Browne RE, Asboe D, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr. 2005;40:41–6.
12. Thomson EC, Fleming VM, Main J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut. 2011;60:837–45.
13. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.
14. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138:e1331–7.
15. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.
16. Grebely J, Petoumenos K, Hellard M, ATAHC Study Group, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology. 2010;52:1216–24.
17. Vogel M, Boesecke C, Rockstroh JK. Acute hepatitis C infection in HIV-positive patients. Curr Opin Infect Dis. 2011;24(1):1–6.
18. Vogel M, Page E, Matthews G, et al. Use of week 4 HCV RNA after acute HCV infection to predict chronic HCV infection. In: 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, California, USA; 2010; abstract 640.
19. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80–8.
20. The European AIDS Treatment Network (NEAT). Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS. 2011;25:399–409.
21. Deterding K, Gruner NH, Wiegand J, et al. Early versus delayed treatment of acute hepatitis C: the German HEP-NET Acute HCV-III study—a randomized controlled trial. 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) 2009: abstract 1047.
22. Nomura H, Sou S, Tanimoto H, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology. 2004;39:1213–9.
23. Vogel M, Nattermann J, Baumgarten A, et al. Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther. 2006;11:1097–101.
24. Dominguez S, Ghosn J, Valantin MA, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS. 2006;20:1157–61.
25. Kruk A. Efficacy of acute HCV treatment with peg-interferon alfa-2b and ribavirin in HIV-infected patients. In: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; Rio de Janeiro; 2005; abstract TuPe1.C01.
26. Piroth L, Larsen C, Binquet C, Steering Committee of the HEPAIG Study, et al. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study. Hepatology. 2010;52:1915–21. doi:10.1002/hep.23959.
27. Laguno M, Martínez-Rebollar M, Perez I, et al. Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients. AIDS Res Hum Retroviruses. 2012;28:1294–300.
28. Dorward J, Garrett N, Scott D, et al. Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration. J Clin Virol. 2011;52:367–9 Epub 2011 Sep 15.
29. Wiegand J, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute–HCV–II study. Hepatology. 2006;43:250–6.
30. Arends JE, van Assen S, Stek CJ, et al. Pegylated interferon-α monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C. Antivir Ther. 2011;16:979–88.
31. Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 2007;23:972–82.
32. Matthews G, Grebely J, Hellard M, et al. Differences in early virological decline in individuals treated within the Australian trial in acute HCV suggest a potential benefit for the use of ribavirin. In: 45th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, Austria; 2010: abstract O60.
33. Hare B, Marks K, Luetkemeyer A, et al. Kinetically guided PEG Alfa-2a and RBV therapy for HIV+adults with acute HCV infection. In: 17th Conference on Retroviruses and Opportunistic Infection; San-Francisco, California, USA; 2010; abstract 639.
34. Nattermann J, Vogel M, Nischalke HD, et al. Genetic variation in IL28B and treatment-induced clearance of hepatitis C Virus in HIV-positive patients with acute and chronic hepatitis C. J Infect Dis. 2011.
35. Lambers F, van den Berk G, van der Meer J, et al. Treatment outcome of acute HCV infection in HIV-infected MSM: effect of treatment length. In: 17th Conference on Retroviruses and Opportunistic Infections. San-Francisco, California, USA; 2010: abstract 641.
36. Vogel M, Dominguez S, Bhagani S, et al. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort. Antivir Ther. 2010;15:267–79.
37. Fierer DS, Dieterich DT, Mullen MP, et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis. 2014;58:873–9.
38. European AIDS Clinical Society (EACS). Guidelines Version 7.1. November 2014.
39. Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010;139:1586–92 1592.e1.
40. Boesecke C, van Assen S, Stellbrink HJ, et al. Peginterferon-alfa mono-therapy in the treatment of acute hepatitis C in HIV-infection. J Viral Hepat. 2014;21:780–5.
41. Grebely J, Hellard M, Applegate T, et al. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS. 2012;26:1653–61.